More than 20 years ago oral tamoxifen was introduced to treat early and advanced breast cancers. Today it is also prescribed after primary treatment for early-stage breast cancer. The drug acts to block the female hormone estrogen, which promotes cancer growth.
Medical oncologists at Beaumont constantly monitor new drugs and protocols to find the best individual treatment plan for each patient. Beaumont maintains a special National Cancer Institute (NCI) designation as a Community Clinical Oncology Program (CCOP), where results from leading-edge clinical studies are integrated into the standard of care. In 2005, the National Cancer Institute awarded Beaumont a five-year grant for continued CCOP research.
Today’s research is every bit as crucial as the studies that first established the value of tamoxifen in treating breast cancer. As new information gleaned from research is quickly applied, patients benefit from the exciting discoveries that improve breast cancer diagnosis and treatment.
To learn more about breast cancer and Beaumont Hospitals’ cancer diagnosis and treatment capabilities, visit the Specialties, Clinical Trials, Cancer Prevention, Diagnosis and Treatment sections of our site
Tamoxifen (Nolvadex ®) is a drug that reduces and/or stops the effects of estrogen (a female hormone) in the body. It was developed over 20 years ago and has been used to treat both advanced and early stage breast cancer. More recently, tamoxifen is being used as an adjuvant, or additional, therapy following primary treatment for early stage breast cancer.
Tamoxifen is taken by mouth in tablet form and is usually prescribed as a single daily dose.
As a breast cancer therapy, tamoxifen works against the effects of estrogen, which has been shown to promote the growth of breast cancer cells. It is often called an "anti-estrogen."
While tamoxifen acts against the effects of estrogen in breast tissue, it acts like estrogen in other body systems. According to the National Cancer Institute, women who take tamoxifen may share many of the beneficial effects of menopausal estrogen replacement therapy, such as a lowering of blood cholesterol and a slowing of bone loss (osteoporosis).
Women considering taking tamoxifen should consult their physician. Different women experience side effects differently. Some of the more common side effects may include:
Less common side effects may include:
Some physicians and researchers caution, however, that tamoxifen therapy may not be appropriate for all women who are at increased risk for breast cancer. Consult your physician for more information regarding your individual case.
Medications recently approved by the US Food and Drug Administration (FDA), called aromatase inhibitors, are used to prevent the recurrence of breast cancer in postmenopausal women. These drugs, such as anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®), prevent estrogen production. Anastrozole is effective only in women who have not had previous hormonal treatment for breast cancer. Letrozole is effective in women who have previously been treated with tamoxifen. Possible side effects of these drugs include osteoporosis or bone fractures.
Another new drug for recurrent breast cancer is fulvestrant (Faslodex®). Also approved by the FDA, this drug eliminates the estrogen receptor rather than blocking it, as is the case with tamoxifen, letrozole, or anastrozole. This drug is used following previous antiestrogen therapy. Side effects for fulvestrant include hot flashes, mild nausea, and fatigue.
Click here to view the
Online Resources of Breast Health
Copyright © 2012 Beaumont Health System. All Rights Reserved.